- Home
- RCUS vs PARR Comparison
RCUS vs PARR Comparison
Compare RCUS & PARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- PARR
- Stock Information
- Founded
- RCUS 2015
- PARR 1984
- Country
- RCUS United States
- PARR United States
- Employees
- RCUS N/A
- PARR N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- PARR Integrated oil Companies
- Sector
- RCUS Health Care
- PARR Energy
- Exchange
- RCUS Nasdaq
- PARR Nasdaq
- Market Cap
- RCUS 1.4B
- PARR 1.2B
- IPO Year
- RCUS 2018
- PARR N/A
- Fundamental
- Price
- RCUS $18.07
- PARR $18.95
- Analyst Decision
- RCUS Strong Buy
- PARR Buy
- Analyst Count
- RCUS 10
- PARR 6
- Target Price
- RCUS $35.88
- PARR $33.17
- AVG Volume (30 Days)
- RCUS 569.4K
- PARR 935.4K
- Earning Date
- RCUS 11-05-2024
- PARR 11-04-2024
- Dividend Yield
- RCUS N/A
- PARR N/A
- EPS Growth
- RCUS N/A
- PARR N/A
- EPS
- RCUS N/A
- PARR 7.96
- Revenue
- RCUS $247,000,000.00
- PARR $8,761,122,000.00
- Revenue This Year
- RCUS $132.82
- PARR N/A
- Revenue Next Year
- RCUS N/A
- PARR N/A
- P/E Ratio
- RCUS N/A
- PARR $2.35
- Revenue Growth
- RCUS 104.13
- PARR 19.45
- 52 Week Low
- RCUS $12.95
- PARR $18.00
- 52 Week High
- RCUS $20.66
- PARR $40.70
- Technical
- Relative Strength Index (RSI)
- RCUS 62.17
- PARR 30.64
- Support Level
- RCUS $15.30
- PARR $18.00
- Resistance Level
- RCUS $17.67
- PARR $19.45
- Average True Range (ATR)
- RCUS 0.82
- PARR 0.75
- MACD
- RCUS 0.01
- PARR -0.27
- Stochastic Oscillator
- RCUS 88.22
- PARR 13.15
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About PARR Par Pacific Holdings Inc.
Par Pacific Holdings Inc is an oil and gas company that manages and maintains interests in energy and infrastructure businesses. The company has three reportable segments namely Refining, Under its refining business, the company produces ultra-low-sulfur diesel, gasoline, jet fuel, marine fuel, LSFO, and other associated refined products. Its Retail includes operation licenses out brands to serve the retail consumer. Through the Logistics segment, crude shipments are delivered to the refineries, in addition to finished products that are exported. It generates maximum revenue from the Refining segment.